These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 15306837

  • 1. At last, a weight neutral insulin?
    Fritsche A, Häring H.
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S41-6. PubMed ID: 15306837
    [Abstract] [Full Text] [Related]

  • 2. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 3. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 4. [Long-acting insulin analogs: progressing slowly].
    Holleman F, Hoekstra JB.
    Ned Tijdschr Geneeskd; 2004 Aug 21; 148(34):1668-9. PubMed ID: 15453117
    [Abstract] [Full Text] [Related]

  • 5. Insulin detemir: a new basal insulin analogue.
    Soran H, Younis N.
    Diabetes Obes Metab; 2006 Jan 21; 8(1):26-30. PubMed ID: 16367879
    [Abstract] [Full Text] [Related]

  • 6. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    Drugs; 2004 Jan 21; 64(22):2577-95. PubMed ID: 15516157
    [Abstract] [Full Text] [Related]

  • 7. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    BioDrugs; 2005 Jan 21; 19(1):67-9. PubMed ID: 15691219
    [Abstract] [Full Text] [Related]

  • 8. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan 21; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 9. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul 03; 48(1238):54-5. PubMed ID: 16841022
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar 03; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 11. Insulin detemir: A historical perspective on a modern basal insulin analogue.
    Meneghini L, Liebl A, Abrahamson MJ.
    Prim Care Diabetes; 2010 Apr 03; 4 Suppl 1():S31-42. PubMed ID: 20394890
    [Abstract] [Full Text] [Related]

  • 12. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH, Nattrass M, Pieber TR.
    Diabetes Metab Res Rev; 2007 Sep 03; 23(6):441-54. PubMed ID: 17668418
    [Abstract] [Full Text] [Related]

  • 13. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov 03; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 14. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN.
    Diabetes Res Clin Pract; 2011 Aug 03; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [Abstract] [Full Text] [Related]

  • 15. Insulin detemir--a new basal insulin analog.
    Goldman-Levine JD, Lee KW.
    Ann Pharmacother; 2005 Mar 03; 39(3):502-7. PubMed ID: 15657117
    [Abstract] [Full Text] [Related]

  • 16. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr 03; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 17. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 03; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 18. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
    Prescrire Int; 2006 Oct 03; 15(85):163-7. PubMed ID: 17121210
    [Abstract] [Full Text] [Related]

  • 19. [Insulin therapy].
    Brunetti P.
    Minerva Endocrinol; 2001 Jun 03; 26(2):65-86. PubMed ID: 11479436
    [Abstract] [Full Text] [Related]

  • 20. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov 03; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.